20 Hospital Physician Board Review Manual www.turner-white.com
vantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer:
a Gynecologic Oncology Group Study. J Clin Oncol.
14. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin
in patients with stage III and stage IV ovarian cancer. N
Engl J Med 1996;334: 1–6.
15. ICON2: randomised trial of single-agent carboplatin against
three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON
Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:1571–6.
16. Ozols RF, Bundy BN, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally
resected stage III ovarian cancer: a Gynecologic Oncology
Group study. J Clinical Oncology 2003;21:3194–200.
17. du Bois A, Luck HJ, Meier W, et al. A randomized clinical
trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as
first-line treatment of ovarian cancer. J Natl Cancer Inst
18. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy
with either single-agent carboplatin or cyclophosphamide,
doxorubicin and cisplatin in women with ovarian cancer: the
ICON 3 randomized trial. Lancet 2002;360(9332):505–15.
19. Vasey PA, Jayson GC, Gordon A, et al; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of
docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer
20. Bookman MA, Brady MF, McGuire WP, et al. Evaluation
of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic
Cancer Intergroup. J Clin Oncol 2009;27:1419–25.
21. Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in
the primary treatment of ovarian cancer. N Engl J Med
22. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3
trial of bevacizumab in ovarian cancer. N Engl J Med
23. Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced
ovarian cancer: a systematic review. J Ovarian Res 2014;
24. Raja FA, Chopra N, Ledermann JA. Optimal first-line
treatment of ovarian cancer. Ann Oncol 2012; 23(suppl
25. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI.
Phase II trial of bevacizumab in persistent or recurrent
epithelial ovarian cancer or primary peritoneal cancer: a
Gynecologic Oncology Group Study. J Clin Oncol 2007;
26. Garcia AA, Hirte H, Fleming G, Yang D, et al. Phase II
clinical trial of bevacizumab and low-dose metronomic oral
cyclophosphamide in recurrent ovarian cancer: a trial of
the California, Chicago, and Princess Margaret Hospital
phase II consortia. J Clin Oncol 2008;26:76–82.
27. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab
combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized
phase III trial. J Clin Oncol 2014;32:1302–8.
28. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial
of chemotherapy with or without bevacizumab in patients
with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol
29. Katsumata N. Dose-dense therapy is of benefit in primary
treatment of ovarian cancer? In favor. Ann Oncol 2011; 22
30. Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systemic review
and meta-analysis of randomized control studies. J Natl
Cancer Inst 2010;102:1845–54.
31. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a
phase 3, open-label, randomized controlled trial. Lancet
32. Katsumata N, Yasuda M, Isonishi S, et al; Japanese Gynecologic Oncology Group. Long-term results of dose-dense
paclitaxel and carboplatin versus conventional paclitaxel
and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG
3016): a randomized, controlled, open-label trial. Lancet
33. van der Burg ME, Boere IA, Berns PM. Dose-dense
therapy is of benefit in primary treatment of ovarian cancer:
contra. Ann Oncol 2011; 22 (suppl 8):33–39.
34. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in
patients with advanced ovarian cancer (MITO- 7): a randomised, multicenter, open-label, phase 3 trial. Lancet
35. Monk BJ, Huang H, Penson SA, et al. Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin
with or without bevacizumab for primary ovarian cancer:
Gynecologic Oncology Group study 262. (Abstract) Gynecol Oncol 2014;133:58 (SGO #139).